NAFLD Genetic Factors and Management

Last reviewed: May 12, 2026 Last updated: May 12, 2026

Written by: Jay Hastings , CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance. His work has included scaling healthcare startups, leading CLIA lab integrations, and helping expand consumer access to precision health tools.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — your resource for evidence-based guidance on liver and metabolic health. Browse all Liver & Metabolic Health education

Nonalcoholic fatty liver disease (NAFLD), recently renamed metabolic dysfunction-associated steatotic liver disease (MASLD), affects roughly a quarter of adults worldwide. It describes fat building up in liver cells in people who drink little or no alcohol. For many, it stays silent for years. Genetics helps explain why two people with similar diets and body weights can have very different liver outcomes.

What NAFLD (MASLD) Actually Is

NAFLD sits on a spectrum. The earliest stage is simple steatosis — fat in the liver with little inflammation. In some people it progresses to steatohepatitis (NASH/MASH), where inflammation and cell injury can lead to fibrosis and, eventually, cirrhosis. The condition rarely produces symptoms early, which is why it is often found incidentally on imaging or through elevated liver enzymes on a routine blood panel.

Weight, insulin resistance, and diet are major drivers. But inherited factors shape how efficiently your liver stores, exports, and remodels fat — and that inherited layer is measurable.

PNPLA3: The Most Studied Fatty Liver Gene

The single strongest genetic signal in fatty liver research is the PNPLA3 variant rs738409 (often written I148M). PNPLA3 encodes a protein involved in remodeling lipid droplets inside liver cells. The I148M variant reduces the protein's normal activity, so fat accumulates and is cleared less efficiently. Carriers, especially those with two copies, show higher liver-fat content and a greater likelihood of progression to inflammation and fibrosis across many populations.

Importantly, PNPLA3 status does not act alone. Its effect is amplified by insulin resistance, excess calories, and a high-sugar diet — which is exactly why lifestyle remains central even for people who carry the higher-risk version.

TM6SF2, GCKR, and Other Named Variants

TM6SF2 (rs58542926, E167K) is the second well-replicated fatty liver gene. It affects how the liver packages and exports fat as very-low-density lipoprotein. The higher-risk variant traps more fat in the liver but, interestingly, is linked to lower blood lipids — a reminder that one variant can push risk in two directions at once.

GCKR influences glucose and lipid handling, and HSD17B13 variants appear to be protective, reducing the risk of progression. Together these genes sketch a personal fat-metabolism profile that goes well beyond a single number on a scale.

How Genes and Lifestyle Interact

Genetics loads the dice; behavior rolls them. Research consistently shows that weight loss of even 7–10% can meaningfully reduce liver fat and inflammation, and this benefit applies to genetic carriers too. A dietary pattern lower in refined sugar and saturated fat, regular physical activity, and management of related conditions such as type 2 diabetes and high triglycerides are the evidence-based levers. None of this is prescriptive advice — it is the general clinical context that a qualified provider tailors to you.

Where Genetic Insight Fits In

Understanding your inherited liver-fat tendencies can make prevention feel less like guesswork. The PlexusDx Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights across metabolic and related biological pathways. It does not diagnose fatty liver disease or tell you what to do about it — it offers pathway-level education about your biology that you and your provider can factor into a broader plan that also includes blood work, imaging when appropriate, and clinical judgment.

Frequently Asked Questions About NAFLD Genetics

Is NAFLD inherited?

NAFLD is not inherited in a simple one-gene pattern, but genetics clearly contributes. Variants in PNPLA3 and TM6SF2 raise the tendency to store liver fat and progress to inflammation. Diet, weight, and insulin resistance still strongly shape whether that inherited tendency ever becomes clinically significant.

Does the PNPLA3 variant mean I will get liver disease?

No. Carrying the PNPLA3 rs738409 variant raises statistical risk, not certainty. Many carriers never develop advanced disease, particularly those who maintain a healthy weight and limit refined sugar and alcohol. It is a marker of tendency, not a diagnosis, and it should be interpreted with a healthcare provider.

Can I change my genetic risk for fatty liver?

You cannot change your genotype, but you can strongly influence its expression. Weight management, reduced sugar intake, physical activity, and control of blood glucose and lipids all lower liver fat in studies, including in people who carry higher-risk variants. Genetics is a guide, not a fixed outcome.

Curious how your own biology reads at the pathway level? The Precision Peptide Genetic Test analyzes 14 pathways, 49 peptides, 150+ genetic insights — giving you educational context about the pathways discussed here, not a diagnosis. Genetics is a guide, not a guarantee, and your results are a starting point for a conversation with your provider.

The Precision Peptide Genetic Test analyzes how your genes influence peptide-related biological pathways. It does not recommend, prescribe, or determine which peptides you should use, and it does not diagnose, treat, or prevent any condition. Consult a qualified healthcare provider before beginning any peptide protocol or making changes to your care.

This article is part of the PlexusDx Education Hub. Browse all Liver & Metabolic Health education

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance. References are included at the end of the article when scientific, medical, or health-related claims are discussed.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.